首页> 外文OA文献 >Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

【2h】

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

机译：将药剂添加到Bevacizumab /紫杉烷方案中的疗效和安全性用于局部复发或转移性乳腺癌的一线治疗Her2阴性患者的一线治疗：来自七项随机对照试验的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Xiao-Qun Liu; Xiangdong Liu; Tiankui Qiao; Wei Chen; Sujuan Yuan;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials [J] . Xiaoqun Liu, Xiangdong Liu, Tiankui Qiao, OncoTargets and therapy . 2016,第6期

机译：贝伐单抗/紫杉烷方案中添加药物对局部复发或转移性乳腺癌Her2阴性患者的一线治疗的有效性和安全性：七项随机对照试验的结果
2. 5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [J] . V.Dieras, J.Glaspy, A.Brufsky, European Journal of Cancer Supplements . 2009,第2期

机译：5016 RIBBON-1患者亚组的疗效，一项随机，双盲，III期化疗方案，伴或不伴贝伐单抗（B），用于一线治疗HER2阴性的局部复发或转移性乳腺癌（MBC）
3. Safety and efficacy of first-line bevacizumab combined with taxane therapy in Chinese patients with HER2-negative locally recurrent or metastatic breast cancer: findings from the ATHENA study [J] . XU Bing-he, TONG Zhong-sheng, QIN Shu-kui, 中华医学杂志（英文版） . 2012,第005期

机译：一线贝伐单抗联合紫杉烷治疗在中国HER2阴性局部复发或转移性乳腺癌患者中的安全性和有效性：ATHENA研究发现
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. Results of a randomized, controlled trial to assess the toxicity and patient adherence with two short-course regimens for the prevention of tuberculosis, a two-month regimen of rifampin and pyrazinamide or a four-month regimen of rifampin only, in comparison with a control regimen of six-months-isoniazid. [D] . Geiter, Lawrence James. 1997

机译：与对照相比，采用两种短期疗程预防结核病，两个月利福平和吡嗪酰胺治疗或仅四个月利福平治疗，评估毒性和患者依从性的随机对照试验结果六个月异烟肼的治疗方案。
6. Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials [O] . Xiaoqun Liu, Xiangdong Liu, Tiankui Qiao, 2016

机译：贝伐单抗/紫杉烷方案中添加药物对局部复发或转移性乳腺癌Her2阴性患者的一线治疗的有效性和安全性：七项随机对照试验的结果
7. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer [O] . Vrdoljak E., Marschner N., Zielinski C., 2016

机译：贝伐单抗治疗HER2阴性的局部复发/转移性乳腺癌的一线贝伐单抗治疗进展后的TANIA TANIA随机III期临床试验的最终结果

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

著录项

引文网络

相似文献

相关主题

期刊订阅